ECSP10010227A - Compuestos de 1,2,4,-triazin-3,5-diona adecuados para el tratamiento de trastornos que responden a la modulación del receptor de dopamina d3 - Google Patents
Compuestos de 1,2,4,-triazin-3,5-diona adecuados para el tratamiento de trastornos que responden a la modulación del receptor de dopamina d3Info
- Publication number
- ECSP10010227A ECSP10010227A EC2010010227A ECSP10010227A ECSP10010227A EC SP10010227 A ECSP10010227 A EC SP10010227A EC 2010010227 A EC2010010227 A EC 2010010227A EC SP10010227 A ECSP10010227 A EC SP10010227A EC SP10010227 A ECSP10010227 A EC SP10010227A
- Authority
- EC
- Ecuador
- Prior art keywords
- alkyl
- fluorinated
- dopamine
- compounds
- cycloalkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 title abstract 4
- 229960003638 dopamine Drugs 0.000 title abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 229940088353 Dopamine D3 receptor antagonist Drugs 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 229930195734 saturated hydrocarbon Natural products 0.000 abstract 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Compuestos de la fórmula I: en donde A es una cadena hidrocarbonada saturada o insaturada que tiene una longitud de cadena de 4 a 6 átomos de carbono, donde la cadena hidrocarbonada no está sustituida o está sustituida por 1, 2 ó 3 grupos metilo;R1 se selecciona del grupo formado por hidrógeno, C1-C3 alquilo y alquilo C1-C3 fluorado;R2 es hidrógeno, halógeno, ciano, C1-C3 alquilo, C1-C3 alcoxi, alquilo C1-C3 fluorado o alcoxi C1-C3 fluorado;R3 se selecciona del grupo formado por alquilo C4-C6 alquilo ramificado y cicloalquilo C3-C6, yR4 es alquilo C1-C6, cicloalquilo C3-C6, alquilo C1-C3 fluorado y cicloalquilo C3-C6 fluorado.y las sales tolerables para uso fisiológico de estos compuestos y sus N-óxidos.La invención también se relaciona con una composición farmacéutica que comprende al menos un compuesto de la fórmula I y/o al menos una sal de adición ácida tolerable para uso fisiológico del mismo, y además con un método para tratar trastornos que responden beneficiosamente a antagonistas del receptor de dopamina D3 o agonistas de dopamina D3, donde dicho método comprende administrar una cantidad eficaz de al menos un compuesto o una sal de adicíón ácida tolerable para uso fisiológico de la fórmula I a un sujeto que lo necesita.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07119927 | 2007-11-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP10010227A true ECSP10010227A (es) | 2010-08-31 |
Family
ID=40210491
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2010010227A ECSP10010227A (es) | 2007-11-02 | 2010-06-01 | Compuestos de 1,2,4,-triazin-3,5-diona adecuados para el tratamiento de trastornos que responden a la modulación del receptor de dopamina d3 |
Country Status (29)
Country | Link |
---|---|
US (1) | US8492540B2 (es) |
EP (1) | EP2217593B1 (es) |
JP (1) | JP5559694B2 (es) |
KR (1) | KR20100094491A (es) |
CN (1) | CN101932574B (es) |
AR (1) | AR069150A1 (es) |
AT (1) | ATE556069T1 (es) |
AU (1) | AU2008320814B2 (es) |
BR (1) | BRPI0818726A2 (es) |
CA (1) | CA2704533C (es) |
CL (1) | CL2008003253A1 (es) |
CO (1) | CO6280473A2 (es) |
CR (1) | CR11410A (es) |
DO (1) | DOP2010000126A (es) |
EC (1) | ECSP10010227A (es) |
ES (1) | ES2386691T3 (es) |
HK (1) | HK1146628A1 (es) |
IL (1) | IL205468A0 (es) |
MX (1) | MX2010004830A (es) |
MY (1) | MY154066A (es) |
NZ (1) | NZ585051A (es) |
PA (1) | PA8802101A1 (es) |
PE (1) | PE20090950A1 (es) |
RU (1) | RU2478633C2 (es) |
TW (1) | TWI463984B (es) |
UA (1) | UA99634C2 (es) |
UY (1) | UY31448A1 (es) |
WO (1) | WO2009056625A1 (es) |
ZA (1) | ZA201003593B (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014025993A1 (en) * | 2012-08-08 | 2014-02-13 | The Johns Hopkins University | Inhibitors of d-amino acid oxidase |
US9376396B2 (en) | 2012-10-22 | 2016-06-28 | AbbVie Deutschland GmbH & Co. KG | Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor |
UY35420A (es) | 2013-03-15 | 2014-10-31 | Abbvie Inc | Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3 |
AR095264A1 (es) | 2013-03-15 | 2015-09-30 | Abbvie Deutschland | Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3 |
KR102643833B1 (ko) | 2022-06-30 | 2024-03-06 | 현대제철 주식회사 | 이강종 연연주시 강종 예측 정합성 증대 방법 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4425143A1 (de) | 1994-07-15 | 1996-01-18 | Basf Ag | Substituierte Pyrimidinverbindungen und deren Verwendung |
DE4425144A1 (de) | 1994-07-15 | 1996-01-18 | Basf Ag | Triazolverbindungen und deren Verwendung |
DE4425146A1 (de) | 1994-07-15 | 1996-01-18 | Basf Ag | Verwendung heterocyclischer Verbindungen |
FR2727682A1 (fr) | 1994-12-02 | 1996-06-07 | Pf Medicament | Nouveaux derives de 3,5-dioxo-(2h,4h)-1,2,4-triazines, leur preparation et leur application a titre de medicament |
DE19728996A1 (de) | 1997-07-07 | 1999-01-14 | Basf Ag | Triazolverbindungen und deren Verwendung |
FR2769913B1 (fr) * | 1997-10-16 | 2000-03-10 | Pf Medicament | Nouveaux derives cyclohexaniques difonctionnalises en 1, 4, leur preparation et leur application therapeutique humaine |
DE10311065A1 (de) | 2003-03-13 | 2004-09-23 | Abbott Gmbh & Co. Kg | Pyrimidin-2-on-Verbindungen und ihre therapeutische Verwendung |
TW200510395A (en) * | 2003-06-05 | 2005-03-16 | Abbott Gmbh & Co Kg | Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor |
DE102004027358A1 (de) | 2004-06-04 | 2005-12-29 | Abbott Gmbh & Co. Kg | Pyrimidinverbindungen und ihre Verwendung |
DE102004027359A1 (de) * | 2004-06-04 | 2005-12-29 | Abbott Gmbh & Co. Kg | Pyridin-2-onverbindungen und deren Verwendung |
DE602005018366D1 (de) * | 2004-08-09 | 2010-01-28 | Abbott Gmbh & Co Kg | Zur behandlung von auf eine modulation des dopamin-d3-rezeptors ansprechende erkrankungen geeignete 4-piperazinylpyrimidinverbindungen |
CN101384263A (zh) * | 2004-12-02 | 2009-03-11 | 艾博特股份有限两合公司 | 适合治疗对多巴胺d3受体调节产生反应的疾病的三唑化合物 |
DE102004061593A1 (de) * | 2004-12-21 | 2006-06-22 | Abbott Gmbh & Co. Kg | Substituierte N-heterocyclische Verbindungen und ihre therapeutische Verwendung |
CA2692268A1 (en) * | 2007-06-28 | 2009-01-08 | Intervet International B.V. | Substituted piperazines as cb1 antagonists |
-
2008
- 2008-10-29 PA PA20088802101A patent/PA8802101A1/es unknown
- 2008-10-30 TW TW097141858A patent/TWI463984B/zh not_active IP Right Cessation
- 2008-10-30 CL CL2008003253A patent/CL2008003253A1/es unknown
- 2008-10-31 PE PE2008001865A patent/PE20090950A1/es not_active Application Discontinuation
- 2008-10-31 WO PCT/EP2008/064795 patent/WO2009056625A1/en active Application Filing
- 2008-10-31 ES ES08844723T patent/ES2386691T3/es active Active
- 2008-10-31 NZ NZ585051A patent/NZ585051A/en not_active IP Right Cessation
- 2008-10-31 UY UY31448A patent/UY31448A1/es not_active Application Discontinuation
- 2008-10-31 AT AT08844723T patent/ATE556069T1/de active
- 2008-10-31 US US12/740,714 patent/US8492540B2/en active Active
- 2008-10-31 AR ARP080104789A patent/AR069150A1/es unknown
- 2008-10-31 CA CA2704533A patent/CA2704533C/en not_active Expired - Fee Related
- 2008-10-31 JP JP2010531532A patent/JP5559694B2/ja not_active Expired - Fee Related
- 2008-10-31 CN CN200880124247.7A patent/CN101932574B/zh not_active Expired - Fee Related
- 2008-10-31 RU RU2010122337/04A patent/RU2478633C2/ru not_active IP Right Cessation
- 2008-10-31 UA UAA201006793A patent/UA99634C2/ru unknown
- 2008-10-31 EP EP08844723A patent/EP2217593B1/en active Active
- 2008-10-31 BR BRPI0818726 patent/BRPI0818726A2/pt not_active IP Right Cessation
- 2008-10-31 MX MX2010004830A patent/MX2010004830A/es active IP Right Grant
- 2008-10-31 KR KR1020107011975A patent/KR20100094491A/ko not_active Application Discontinuation
- 2008-10-31 AU AU2008320814A patent/AU2008320814B2/en not_active Ceased
- 2008-10-31 MY MYPI2010001969A patent/MY154066A/en unknown
-
2010
- 2010-04-29 IL IL205468A patent/IL205468A0/en unknown
- 2010-04-29 DO DO2010000126A patent/DOP2010000126A/es unknown
- 2010-05-03 CR CR11410A patent/CR11410A/es unknown
- 2010-05-20 ZA ZA2010/03593A patent/ZA201003593B/en unknown
- 2010-06-01 EC EC2010010227A patent/ECSP10010227A/es unknown
- 2010-06-01 CO CO10065792A patent/CO6280473A2/es active IP Right Grant
-
2011
- 2011-01-25 HK HK11100717.9A patent/HK1146628A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2621140T3 (es) | Compuestos ácido acilamino y preparaciones alimenticias que los contienen | |
SV2011003809A (es) | Derivados de heteroarilo como inhibidores de dgat1 | |
AR061644A1 (es) | Derivados de benzofurano | |
PE20121048A1 (es) | Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17 | |
GT200500242A (es) | Procesos para la preparaciòn de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas | |
CO6140053A2 (es) | Proceso para fabricar 2-amino-5-halobenzamidas 3-sustituidas | |
ECSP10010227A (es) | Compuestos de 1,2,4,-triazin-3,5-diona adecuados para el tratamiento de trastornos que responden a la modulación del receptor de dopamina d3 | |
AR072166A1 (es) | Derivado de piperidina y su uso como inhibidor de renina superior | |
PE20201165A1 (es) | Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
ECSP066968A (es) | Compuestos de metil-aril o heteroaril-amida sustituida | |
PA8848201A1 (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes | |
ES2531009T3 (es) | Análogos sustituidos de dicetopiperazina para su uso como agentes para la administración de fármacos | |
ECSP099330A (es) | Compuesto de indol | |
NI200900164A (es) | COMPUESTOS AMINO- 5 -[ -4- (DIFLUOROMETOXI) FENIL SUSTITUIDO] -5- FENILIMIDAZOLONA COMO INHIBIDORES DE Beta - SECRETASA. | |
AR069335A1 (es) | Inhibidores de la replicacion del virus de la inmunodeficiencia humana | |
BRPI0617918B8 (pt) | compostos de fórmula (i) e seu uso, medicamentos e composição farmacêutica | |
AR066268A1 (es) | Compuesto de imidazol sustituido y su uso | |
AR081819A1 (es) | Derivados de pirimidil-piperidinil-oxipiridinona, composiciones farmaceuticas que los contienen y uso de los mismos para tratar diabetes, dislipemias, obesidad y otras enfermedades | |
ES2606839T3 (es) | Tetraaza-ciclopenta[a]indenilo y su uso como moduladores alostéricos positivos | |
PE20090593A1 (es) | Compuestos heterociclos como antagonistas del receptor de bradiquinina b1 | |
AR069607A1 (es) | Inhibidores de la estearoil-coa desaturasa | |
AR066242A1 (es) | Tia(di)azoles como antagonistas del recpetor de dopamina 2 de disociacion rapida | |
DOP2011000296A (es) | Compuesto de pirazol | |
CR11860A (es) | Derivados de dibenzotiazepina y sus usos - 424 | |
PE20190657A1 (es) | Compuestos de indazol para usar en lesiones de tendones y/o ligamentos |